Skip to main content

Breadcrumb

  1. Home

National Committee for Quality Assurance

Follow-Up After Emergency Department Visit for Mental Illness or Alcohol and Other Drug Abuse or Dependence

  • The percentage of discharges for patients 18 years of age and older who had a visit to the emergency department with a primary diagnosis of mental health or alcohol or other drug dependence during the measurement year AND who had a follow-up visit with any provider with a corresponding primary diagnosis of mental health or alcohol or other drug dependence within 7- and 30-days of discharge.

    Four rates are reported:
    - The percentage of emergency department visits for mental health for which the patient received follow-up within 7 days of discharge.

    CBE ID
    2605

Follow-Up After Hospitalization for Mental Illness (FUH)

  • The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider. Two rates are reported:
    1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
    2. The percentage of discharges for which the member received follow-up within 7 days after discharge.

    CBE ID
    0576

Follow-Up After Hospitalization for Schizophrenia (7- and 30-day)

  • The percentage of discharges for individuals 18 – 64 years of age who were hospitalized for treatment of schizophrenia and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner. Two rates are reported.
    •The percentage of individuals who received follow-up within 30 days of discharge
    •The percentage of individuals who received follow-up within 7 days of discharge

    CBE ID
    1937

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

  • Percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of which is within 30 days of when the first ADHD medication was dispensed.
    An Initiation Phase Rate and Continuation and Maintenance Phase Rate are reported.

    CBE ID
    0108

Frequency of Ongoing Prenatal Care (FPC)

  • The percentage of Medicaid deliveries that had the following number of expected prenatal visits:

    • less than 21 percent of expected visits.

    • 21 percent–40 percent of expected visits.

    • 41 percent–60 percent of expected visits.

    • 61 percent–80 percent of expected visits.

    • greater than or equal to 81 percent of expected visits.

    CBE ID
    1391

Healthy Physical Development by 13 Years of Age

  • The percentage of children 13 years of age who had healthy physical development services. The measure has four rates: BMI Assessment, Physical Activity Counseling, Nutrition Counseling and Screen Time Counseling.

    CBE ID
    1512

Healthy Physical Development by 18 Years of Age

  • The percentage of children 18 years of age who had healthy physical development services. The measure has four rates: BMI Assessment, Physical Activity Counseling, Nutrition Counseling and Screen Time Counseling

    CBE ID
    1514

Healthy Physical Development by 6 Years of Age

  • The percentage of children 6 years of age who had healthy physical development services. The measure has four rates: BMI Assessment, Physical Activity Counseling, Nutrition Counseling and Screen Time Counseling.

    CBE ID
    1396

HIV/AIDS: Adolescent and Adult Patients who are Prescribed Potent Antiretroviral Therapy

  • Percentage of patients with a diagnosis of HIV/AIDS, with at least two visits during the measurement year, with at least 90 days between each visit: aged 13 years and older who have a history of a CD4 count less than or equal to 500 cells/mm3; aged 13 years and older who have a history of an AIDS-defining illness, regardless of CD4 count; or who are pregnant, regardless of CD4 count or age, who were prescribed potent antiretroviral therapy

    CBE ID
    0406